Janus Henderson Group PLC Invests $1.16 Million in Astrana Health, Inc. (NASDAQ:ASTH)

Janus Henderson Group PLC bought a new stake in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 20,106 shares of the company's stock, valued at approximately $1,164,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC bought a new position in shares of Astrana Health during the 3rd quarter worth approximately $34,000. Nisa Investment Advisors LLC bought a new position in shares of Astrana Health during the third quarter valued at $35,000. KBC Group NV acquired a new stake in shares of Astrana Health in the 3rd quarter valued at $70,000. Quest Partners LLC bought a new stake in shares of Astrana Health in the 3rd quarter worth about $133,000. Finally, Central Pacific Bank Trust Division acquired a new stake in shares of Astrana Health during the 3rd quarter worth about $160,000. 52.77% of the stock is owned by institutional investors.

Astrana Health Price Performance

Shares of Astrana Health stock traded down $0.11 during midday trading on Friday, reaching $37.63. The company had a trading volume of 214,231 shares, compared to its average volume of 212,564. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock has a fifty day simple moving average of $49.49 and a 200 day simple moving average of $48.08. Astrana Health, Inc. has a 1-year low of $34.11 and a 1-year high of $63.20. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of 28.95, a price-to-earnings-growth ratio of 1.80 and a beta of 1.13.

Astrana Health (NASDAQ:ASTH - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The company had revenue of $478.71 million during the quarter, compared to analysts' expectations of $462.01 million. During the same period last year, the firm earned $0.47 EPS. As a group, equities research analysts forecast that Astrana Health, Inc. will post 1.16 earnings per share for the current year.

Wall Street Analyst Weigh In

ASTH has been the topic of a number of recent analyst reports. KeyCorp assumed coverage on shares of Astrana Health in a research report on Friday, October 11th. They issued a "sector weight" rating on the stock. Robert W. Baird boosted their target price on Astrana Health from $67.00 to $86.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. BTIG Research raised their price target on Astrana Health from $60.00 to $70.00 and gave the company a "buy" rating in a report on Thursday, October 3rd. Finally, TD Cowen assumed coverage on Astrana Health in a research report on Monday, October 14th. They issued a "buy" rating and a $66.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Astrana Health currently has an average rating of "Buy" and a consensus target price of $65.17.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.